The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Community-acquired Bacterial Pneumonia Market Research Report 2025
Synopsis
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Community-acquired Bacterial Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community-acquired Bacterial Pneumonia.
Report Scope
The Community-acquired Bacterial Pneumonia market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Community-acquired Bacterial Pneumonia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Community-acquired Bacterial Pneumonia companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
Segment by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community-acquired Bacterial Pneumonia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Community-acquired pneumonia (CAP) refers to pneumonia that is acquired in the community setting, which is caused by various bacterial species, such as S. pneumoniae, Haemophilus influenzae type b (Hib), Chlamydia pneumoniae, Mycoplasma, pneumoniae, or Legionella spp., and many others. Prevalence of pneumonia differs both regionally and by age group affecting from children to adults.
The global Community-acquired Bacterial Pneumonia market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Community-acquired Bacterial Pneumonia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Community-acquired Bacterial Pneumonia.
Report Scope
The Community-acquired Bacterial Pneumonia market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Community-acquired Bacterial Pneumonia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Community-acquired Bacterial Pneumonia companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Nabriva Therapeutics
Paratek Pharmaceuticals
Melinta Therapeutics
Allergan plc
Bayer AG
Lupin Pharmaceuticals
Mylan N.V.
Sanofi S.A.
Pfizer Inc.
Dainippon Sumitomo Pharma
Takeda Pharmaceutical Company Limited
Basilea Pharmaceutica International AG
Segment by Type
Pleuromutilin Antibiotic
Cephalosporin
Glycylcycline
Oxazolidinone
Ketolide
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community-acquired Bacterial Pneumonia companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pleuromutilin Antibiotic
1.2.3 Cephalosporin
1.2.4 Glycylcycline
1.2.5 Oxazolidinone
1.2.6 Ketolide
1.2.7 Others
1.3 Market by Application
1.3.1 Global Community-acquired Bacterial Pneumonia Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Community-acquired Bacterial Pneumonia Market Perspective (2019-2030)
2.2 Community-acquired Bacterial Pneumonia Growth Trends by Region
2.2.1 Global Community-acquired Bacterial Pneumonia Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Community-acquired Bacterial Pneumonia Historic Market Size by Region (2019-2024)
2.2.3 Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2025-2030)
2.3 Community-acquired Bacterial Pneumonia Market Dynamics
2.3.1 Community-acquired Bacterial Pneumonia Industry Trends
2.3.2 Community-acquired Bacterial Pneumonia Market Drivers
2.3.3 Community-acquired Bacterial Pneumonia Market Challenges
2.3.4 Community-acquired Bacterial Pneumonia Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue
3.1.1 Global Top Community-acquired Bacterial Pneumonia Players by Revenue (2019-2024)
3.1.2 Global Community-acquired Bacterial Pneumonia Revenue Market Share by Players (2019-2024)
3.2 Global Community-acquired Bacterial Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Community-acquired Bacterial Pneumonia Revenue
3.4 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio
3.4.1 Global Community-acquired Bacterial Pneumonia Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Community-acquired Bacterial Pneumonia Revenue in 2023
3.5 Community-acquired Bacterial Pneumonia Key Players Head office and Area Served
3.6 Key Players Community-acquired Bacterial Pneumonia Product Solution and Service
3.7 Date of Enter into Community-acquired Bacterial Pneumonia Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Community-acquired Bacterial Pneumonia Breakdown Data by Type
4.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Type (2019-2024)
4.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2025-2030)
5 Community-acquired Bacterial Pneumonia Breakdown Data by Application
5.1 Global Community-acquired Bacterial Pneumonia Historic Market Size by Application (2019-2024)
5.2 Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Community-acquired Bacterial Pneumonia Market Size (2019-2030)
6.2 North America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024)
6.4 North America Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Community-acquired Bacterial Pneumonia Market Size (2019-2030)
7.2 Europe Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024)
7.4 Europe Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size (2019-2030)
8.2 Asia-Pacific Community-acquired Bacterial Pneumonia Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2019-2024)
8.4 Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Community-acquired Bacterial Pneumonia Market Size (2019-2030)
9.2 Latin America Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024)
9.4 Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size (2019-2030)
10.2 Middle East & Africa Community-acquired Bacterial Pneumonia Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024)
10.4 Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nabriva Therapeutics
11.1.1 Nabriva Therapeutics Company Detail
11.1.2 Nabriva Therapeutics Business Overview
11.1.3 Nabriva Therapeutics Community-acquired Bacterial Pneumonia Introduction
11.1.4 Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.1.5 Nabriva Therapeutics Recent Development
11.2 Paratek Pharmaceuticals
11.2.1 Paratek Pharmaceuticals Company Detail
11.2.2 Paratek Pharmaceuticals Business Overview
11.2.3 Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
11.2.4 Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.2.5 Paratek Pharmaceuticals Recent Development
11.3 Melinta Therapeutics
11.3.1 Melinta Therapeutics Company Detail
11.3.2 Melinta Therapeutics Business Overview
11.3.3 Melinta Therapeutics Community-acquired Bacterial Pneumonia Introduction
11.3.4 Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.3.5 Melinta Therapeutics Recent Development
11.4 Allergan plc
11.4.1 Allergan plc Company Detail
11.4.2 Allergan plc Business Overview
11.4.3 Allergan plc Community-acquired Bacterial Pneumonia Introduction
11.4.4 Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.4.5 Allergan plc Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Community-acquired Bacterial Pneumonia Introduction
11.5.4 Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.5.5 Bayer AG Recent Development
11.6 Lupin Pharmaceuticals
11.6.1 Lupin Pharmaceuticals Company Detail
11.6.2 Lupin Pharmaceuticals Business Overview
11.6.3 Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Introduction
11.6.4 Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.6.5 Lupin Pharmaceuticals Recent Development
11.7 Mylan N.V.
11.7.1 Mylan N.V. Company Detail
11.7.2 Mylan N.V. Business Overview
11.7.3 Mylan N.V. Community-acquired Bacterial Pneumonia Introduction
11.7.4 Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.7.5 Mylan N.V. Recent Development
11.8 Sanofi S.A.
11.8.1 Sanofi S.A. Company Detail
11.8.2 Sanofi S.A. Business Overview
11.8.3 Sanofi S.A. Community-acquired Bacterial Pneumonia Introduction
11.8.4 Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.8.5 Sanofi S.A. Recent Development
11.9 Pfizer Inc.
11.9.1 Pfizer Inc. Company Detail
11.9.2 Pfizer Inc. Business Overview
11.9.3 Pfizer Inc. Community-acquired Bacterial Pneumonia Introduction
11.9.4 Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.9.5 Pfizer Inc. Recent Development
11.10 Dainippon Sumitomo Pharma
11.10.1 Dainippon Sumitomo Pharma Company Detail
11.10.2 Dainippon Sumitomo Pharma Business Overview
11.10.3 Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Introduction
11.10.4 Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.10.5 Dainippon Sumitomo Pharma Recent Development
11.11 Takeda Pharmaceutical Company Limited
11.11.1 Takeda Pharmaceutical Company Limited Company Detail
11.11.2 Takeda Pharmaceutical Company Limited Business Overview
11.11.3 Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Introduction
11.11.4 Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.11.5 Takeda Pharmaceutical Company Limited Recent Development
11.12 Basilea Pharmaceutica International AG
11.12.1 Basilea Pharmaceutica International AG Company Detail
11.12.2 Basilea Pharmaceutica International AG Business Overview
11.12.3 Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Introduction
11.12.4 Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024)
11.12.5 Basilea Pharmaceutica International AG Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Community-acquired Bacterial Pneumonia Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Pleuromutilin Antibiotic
Table 3. Key Players of Cephalosporin
Table 4. Key Players of Glycylcycline
Table 5. Key Players of Oxazolidinone
Table 6. Key Players of Ketolide
Table 7. Key Players of Others
Table 8. Global Community-acquired Bacterial Pneumonia Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Community-acquired Bacterial Pneumonia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Community-acquired Bacterial Pneumonia Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Community-acquired Bacterial Pneumonia Market Share by Region (2019-2024)
Table 12. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Community-acquired Bacterial Pneumonia Market Share by Region (2025-2030)
Table 14. Community-acquired Bacterial Pneumonia Market Trends
Table 15. Community-acquired Bacterial Pneumonia Market Drivers
Table 16. Community-acquired Bacterial Pneumonia Market Challenges
Table 17. Community-acquired Bacterial Pneumonia Market Restraints
Table 18. Global Community-acquired Bacterial Pneumonia Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Community-acquired Bacterial Pneumonia Market Share by Players (2019-2024)
Table 20. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2023)
Table 21. Ranking of Global Top Community-acquired Bacterial Pneumonia Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Community-acquired Bacterial Pneumonia Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Community-acquired Bacterial Pneumonia Product Solution and Service
Table 25. Date of Enter into Community-acquired Bacterial Pneumonia Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Community-acquired Bacterial Pneumonia Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2019-2024)
Table 29. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Type (2025-2030)
Table 31. Global Community-acquired Bacterial Pneumonia Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2019-2024)
Table 33. Global Community-acquired Bacterial Pneumonia Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Community-acquired Bacterial Pneumonia Revenue Market Share by Application (2025-2030)
Table 35. North America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size by Country (2025-2030) & (US$ Million)
Table 50. Nabriva Therapeutics Company Detail
Table 51. Nabriva Therapeutics Business Overview
Table 52. Nabriva Therapeutics Community-acquired Bacterial Pneumonia Product
Table 53. Nabriva Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 54. Nabriva Therapeutics Recent Development
Table 55. Paratek Pharmaceuticals Company Detail
Table 56. Paratek Pharmaceuticals Business Overview
Table 57. Paratek Pharmaceuticals Community-acquired Bacterial Pneumonia Product
Table 58. Paratek Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 59. Paratek Pharmaceuticals Recent Development
Table 60. Melinta Therapeutics Company Detail
Table 61. Melinta Therapeutics Business Overview
Table 62. Melinta Therapeutics Community-acquired Bacterial Pneumonia Product
Table 63. Melinta Therapeutics Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 64. Melinta Therapeutics Recent Development
Table 65. Allergan plc Company Detail
Table 66. Allergan plc Business Overview
Table 67. Allergan plc Community-acquired Bacterial Pneumonia Product
Table 68. Allergan plc Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 69. Allergan plc Recent Development
Table 70. Bayer AG Company Detail
Table 71. Bayer AG Business Overview
Table 72. Bayer AG Community-acquired Bacterial Pneumonia Product
Table 73. Bayer AG Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 74. Bayer AG Recent Development
Table 75. Lupin Pharmaceuticals Company Detail
Table 76. Lupin Pharmaceuticals Business Overview
Table 77. Lupin Pharmaceuticals Community-acquired Bacterial Pneumonia Product
Table 78. Lupin Pharmaceuticals Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 79. Lupin Pharmaceuticals Recent Development
Table 80. Mylan N.V. Company Detail
Table 81. Mylan N.V. Business Overview
Table 82. Mylan N.V. Community-acquired Bacterial Pneumonia Product
Table 83. Mylan N.V. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 84. Mylan N.V. Recent Development
Table 85. Sanofi S.A. Company Detail
Table 86. Sanofi S.A. Business Overview
Table 87. Sanofi S.A. Community-acquired Bacterial Pneumonia Product
Table 88. Sanofi S.A. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 89. Sanofi S.A. Recent Development
Table 90. Pfizer Inc. Company Detail
Table 91. Pfizer Inc. Business Overview
Table 92. Pfizer Inc. Community-acquired Bacterial Pneumonia Product
Table 93. Pfizer Inc. Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 94. Pfizer Inc. Recent Development
Table 95. Dainippon Sumitomo Pharma Company Detail
Table 96. Dainippon Sumitomo Pharma Business Overview
Table 97. Dainippon Sumitomo Pharma Community-acquired Bacterial Pneumonia Product
Table 98. Dainippon Sumitomo Pharma Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 99. Dainippon Sumitomo Pharma Recent Development
Table 100. Takeda Pharmaceutical Company Limited Company Detail
Table 101. Takeda Pharmaceutical Company Limited Business Overview
Table 102. Takeda Pharmaceutical Company Limited Community-acquired Bacterial Pneumonia Product
Table 103. Takeda Pharmaceutical Company Limited Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 104. Takeda Pharmaceutical Company Limited Recent Development
Table 105. Basilea Pharmaceutica International AG Company Detail
Table 106. Basilea Pharmaceutica International AG Business Overview
Table 107. Basilea Pharmaceutica International AG Community-acquired Bacterial Pneumonia Product
Table 108. Basilea Pharmaceutica International AG Revenue in Community-acquired Bacterial Pneumonia Business (2019-2024) & (US$ Million)
Table 109. Basilea Pharmaceutica International AG Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Community-acquired Bacterial Pneumonia Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Community-acquired Bacterial Pneumonia Market Share by Type: 2023 VS 2030
Figure 3. Pleuromutilin Antibiotic Features
Figure 4. Cephalosporin Features
Figure 5. Glycylcycline Features
Figure 6. Oxazolidinone Features
Figure 7. Ketolide Features
Figure 8. Others Features
Figure 9. Global Community-acquired Bacterial Pneumonia Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Community-acquired Bacterial Pneumonia Market Share by Application: 2023 VS 2030
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Community-acquired Bacterial Pneumonia Report Years Considered
Figure 15. Global Community-acquired Bacterial Pneumonia Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Community-acquired Bacterial Pneumonia Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Community-acquired Bacterial Pneumonia Market Share by Region: 2023 VS 2030
Figure 18. Global Community-acquired Bacterial Pneumonia Market Share by Players in 2023
Figure 19. Global Top Community-acquired Bacterial Pneumonia Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community-acquired Bacterial Pneumonia as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Community-acquired Bacterial Pneumonia Revenue in 2023
Figure 21. North America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Community-acquired Bacterial Pneumonia Market Share by Country (2019-2030)
Figure 23. United States Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Community-acquired Bacterial Pneumonia Market Share by Country (2019-2030)
Figure 27. Germany Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Community-acquired Bacterial Pneumonia Market Share by Region (2019-2030)
Figure 35. China Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Community-acquired Bacterial Pneumonia Market Share by Country (2019-2030)
Figure 43. Mexico Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Community-acquired Bacterial Pneumonia Market Share by Country (2019-2030)
Figure 47. Turkey Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Community-acquired Bacterial Pneumonia Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Nabriva Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 50. Paratek Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 51. Melinta Therapeutics Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 52. Allergan plc Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 53. Bayer AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 54. Lupin Pharmaceuticals Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 55. Mylan N.V. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 56. Sanofi S.A. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 57. Pfizer Inc. Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 58. Dainippon Sumitomo Pharma Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 59. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 60. Basilea Pharmaceutica International AG Revenue Growth Rate in Community-acquired Bacterial Pneumonia Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
